Up-to-date several Hsp70-targeting tools (e.g., tumor penetrating peptide (TPP), monoclonal antibody cmHsp70.1 and its Fab fragment, serine protease granzyme B, anticalins) have been successfully employed for tumor imaging and therapy in preclinical models9–14. This evidence concerns the gene HSPA1A and neoplasm.